12 articles
European stocks rose near one-week highs led by Genmab, which surged 7.6% after positive late-stage trial results for its blood cancer drug combo with AbbVie. The healthcare sector advanced as bond yi
ADARx Pharmaceuticals secured $446.3 million in an upsized US IPO, with AbbVie investing up to $100 million in a concurrent private placement. The San Diego-based developer plans to advance its lead c
ADARx Pharmaceuticals seeks a $1.74 billion valuation in its U.S. IPO, aiming to raise $371.9 million while AbbVie secures a 4.9% stake through a concurrent private placement ahead of its Nasdaq listi
Investors are shifting capital into U.S. healthcare stocks, driving the S&P 500 healthcare index to record highs amid rising M&A activity and strong earnings forecasts from major drugmakers like AbbVi
AbbVie lowered its 2026 profit forecast to account for the $10.9 billion Apogee Therapeutics acquisition while beating Q2 earnings estimates on strong immunology drug sales.
A U.S. House committee launched an investigation into Merck and AbbVie over clinical trials in China, citing national security and ethical risks. Lawmakers require details on trial sites by July 17 am
US stocks traded mixed as oil prices eased following US-Iran war talks, while pharmaceutical giant AbbVie agreed to acquire Apogee Therapeutics in a $10.9 billion deal.
Evonik plans 3,200 job cuts while AbbVie acquires Apogee for nearly $11 billion. C&EN also promotes recent reporting on heavy rare earth extraction in Brazil to counter China's monopoly.
AbbVie agreed to acquire Apogee Therapeutics for $10.9 billion to strengthen its immunology pipeline ahead of patent expirations. The deal secures access to experimental drug zumilokibart for treating
US stock futures remained subdued as investors tracked US-Iran negotiations impacting oil prices. Meanwhile, AbbVie nears a $10.9 billion deal for Apogee Therapeutics amid broader market optimism driv
AbbVie reported better-than-expected quarterly revenue driven by growth in Skyrizi and Rinvoq, offsetting declines in Humira sales. The company raised its full-year earnings forecast while noting stro
C&EN's 2025 financial wrap-up shows most chemical companies posted lower sales, though DuPont saw growth while redefining its portfolio. Broader watch items include Lyondell reducing sustainability ta
ChemBrief